Iritero 100 Injection contains Irinotecan at a concentration of 20 mg/ml and is indicated for the treatment of metastatic colorectal cancer and other solid tumors as determined by clinical assessment. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the cleavable complex formed between topoisomerase I and DNA, leading to DNA strand breaks and apoptosis in rapidly dividing cancer cells. Administered intravenously, Iritero 100 Injection is typically used as a single agent or in combination with other chemotherapeutic regimens such as fluorouracil and leucovorin. Dosage and administration should be individualized based on patient tolerance, prior therapy, and hematologic parameters. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, and fatigue, necessitating close monitoring of blood counts and supportive care measures. Premedication with antiemetics and atropine may be required to manage cholinergic symptoms and gastrointestinal side effects. Iritero 100 Injection is contraindicated in patients with known hypersensitivity to irinotecan or its components and should be used cautiously in individuals with hepatic impairment. Proper dilution and infusion protocols must be followed to ensure safety and efficacy. This medication should be prescribed and administered by healthcare professionals experienced in chemotherapy management.